文献速递血栓与止血

YAP1通过结合MYH9调控免疫性血小板减少症中的血小板生成

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia.
PubMed 文献 · Blood · 2024-01-01

本研究探讨Yes相关蛋白1(YAP1)在免疫性血小板减少症(ITP)血小板生成中的作用。ITP患者巨核细胞中YAP1表达降低且细胞骨架肌动蛋白排列紊乱;实验性ITP小鼠中YAP1表达降低导致巨核细胞分布异常、晚期巨核细胞比例下降及血小板恢复不足;YAP1激活剂XMU-MP-1可挽救YAP1+/- ITP小鼠和患者的细胞骨架缺陷及血小板生成异常。

要点

  • ITP患者巨核细胞中YAP1表达降低,伴细胞骨架肌动蛋白排列紊乱。
  • YAP1表达降低致实验性ITP小鼠巨核细胞分布异常、晚期巨核细胞比例下降及血小板恢复不足。
  • YAP1激活剂XMU-MP-1可挽救YAP1+/- ITP小鼠和患者的细胞骨架缺陷及血小板生成异常。

核心结论

  • YAP1在血小板生成中起关键作用,可能为ITP的诊断标志物和治疗选择提供潜力。

研究设计与样本

  • 研究检测了ITP患者巨核细胞中YAP1的表达,并使用实验性ITP小鼠模型研究YAP1在血小板生成中的作用。

主要发现

  • ITP患者巨核细胞中YAP1表达降低,且细胞骨架肌动蛋白排列紊乱。
  • 实验性ITP小鼠中YAP1表达降低诱导巨核细胞分布异常、降低晚期巨核细胞占总巨核细胞的比例,并导致血小板恢复不足。
  • GATA结合蛋白1结合YAP1启动子上调YAP1表达,促进巨核细胞成熟。
  • 磷酸化YAP1通过其WW2结构域与肌球蛋白重链9结合,促进细胞骨架活化,从而促进血小板生成。
  • 使用YAP1激活剂XMU-MP-1靶向YAP1足以挽救YAP1+/- ITP小鼠和患者的细胞骨架缺陷及血小板生成异常。

关键数值与推荐

  • ITP患者巨核细胞中YAP1表达降低,伴细胞骨架肌动蛋白排列紊乱。
  • 实验性ITP小鼠中YAP1表达降低导致巨核细胞分布异常、晚期巨核细胞比例下降及血小板恢复不足。
  • GATA结合蛋白1结合YAP1启动子上调YAP1,促进巨核细胞成熟。
  • 磷酸化YAP1通过WW2结构域与肌球蛋白重链9结合,促进细胞骨架活化及血小板生成。
  • YAP1激活剂XMU-MP-1可挽救YAP1+/- ITP小鼠和患者的细胞骨架缺陷及血小板生成异常。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is a complicated bleeding disease characterized by a sharp platelet reduction. As a dominating element involved in ITP, megakaryocytes (MKs) are responsible for thrombopoiesis. However, the mechanism underlying the dysregulation of thrombopoiesis that occurs in ITP remains unidentified. In this study, we examined the role of Yes-associated protein 1 (YAP1) in thrombopoiesis during ITP. We observed reduced YAP1 expression with cytoskeletal actin misalignment in MKs from patients with ITP. Using an experimental ITP mouse model, we showed that reduced YAP1 expression induced aberrant MK distribution, reduced the percentage of late MKs among the total MKs, and caused submaximal platelet recovery. Mechanistically, YAP1 upregulation by binding of GATA-binding protein 1 to its promoter promoted MK maturation. Phosphorylated YAP1 promoted cytoskeletal activation by binding its WW2 domain to myosin heavy chain 9, thereby facilitating thrombopoiesis. Targeting YAP1 with its activator XMU-MP-1 was sufficient to rescue cytoskeletal defects and thrombopoiesis dysregulation in YAP1+/- mice with ITP and patients. Taken together, these results demonstrate the crucial role of YAP1 in thrombopoiesis, providing potential for the development of diagnostic markers and therapeutic options for ITP.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hu S, Liu Y, Zhang X, et al. YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia. Blood. 2024. PMID: 39190466. doi:10.1182/blood.2023023601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。